Superluminal Medicines Inc.
Dylan Morris is a Managing Director at Insight Partners since 2021 and holds multiple Board Director positions across various companies, including Exsilio Therapeutics, Superluminal Medicines Inc., ImmuneBridge, Profluent Bio, Unlearn.AI, Gameto, Capacity Bio, and DEM Biopharma, Inc., all of which commenced in 2022 or 2023. Additionally, Dylan serves as a Board Director for ArrePath since 2021. Dylan holds a Graduate Research degree in Biochemistry and Molecular Biophysics from Caltech and an AB in Computer Science from Harvard University.
This person is not in the org chart
This person is not in any teams
Superluminal Medicines Inc.
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVIDIA and Gaingels.